Zydus bags final USFDA clearance for Ivermectin and Dapsone; details inside
News by Aliceblue News Desk
02 Mar 2026
Introduction
Leading Indian pharmaceutical group received USFDA approvals for Ivermectin 3 mg and Dapsone 25 mg, 100 mg, to be manufactured in Ahmedabad and distributed in the US.
Also Read: BPCL: shares in focus after setting up Singapore subsidiary to expand global energy trading
Share price movement of Zydus Lifesciences
On March 2, 2026, Zydus Lifesciences Ltd opened at ₹835.85, down 9.34% from its previous close of ₹922.50. The stock reached a high of ₹911.80 (-1.15%) and a low of ₹835.85 (-9.34%). By 11:42 AM, it traded at ₹904.00, a 2.01% decrease, with a market cap of ₹90,963.55 crore.
Zydus Secures USFDA Final Approvals
Zydus Lifesciences Limited has received final approvals from the United States Food and Drug Administration for Ivermectin Tablets USP, 3 mg, and Dapsone Tablets USP, 25 mg and 100 mg, the company said in a press release dated February 28, 2026.
Ivermectin Tablets USP, 3 mg, reference listed drug Stromectol®, are indicated for intestinal strongyloidiasis and onchocerciasis. The tablets will be manufactured at the group’s SEZ Ahmedabad facility and distributed by Viona Pharmaceuticals Inc.
Dapsone Tablets USP, 25 mg and 100 mg, are indicated for leprosy and dermatitis herpetiformis. The product will be manufactured at the group’s SEZ-II Ahmedabad facility and distributed by Viona Pharmaceuticals Inc.
Ivermectin Tablets USP, 3 mg, recorded annual sales of USD 14.8 million. Dapsone Tablets USP, 25 mg and 100 mg, reported USD 8.4 million sales in the US. The group now has 434 approvals.
Stock performance of Zydus Lifesciences for period of 1 week, 6 months, and 1 year
Over the past week, the stock gained 1.51%. In the last six months, it declined 8.58%, while over one year, it recorded a 5.14% increase.
Also Read: OneSource Specialty Pharma: NSE & BSE give green signal for merger scheme; here’s details
Shareholding pattern of Zydus Lifesciences
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 75.00% | 75.00% | 75.00% |
| FII | 7.10% | 7.30% | 7.10% |
| DII | 11.10% | 10.90% | 11.10% |
| Public | 6.90% | 6.80% | 6.70% |
About Zydus Lifesciences
Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) is a healthcare group, innovating to meet unmet medical needs, growing from ₹250 crore in 1995 to ₹14,253 crore in FY20.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Zydus Lifesciences Ltd share price in focus today?
A: Zydus Lifesciences gets USFDA approval for Ivermectin 3 mg and Dapsone 25 mg, 100 mg, manufactured in Ahmedabad, distributed by Viona.
Q: What is Zydus Lifesciences Ltd’s main business focus?
A: Zydus Lifesciences focuses on pharmaceuticals, manufacturing and marketing medicines, addressing unmet healthcare needs globally, and innovating in drug development.
Q: What are the 52-week high and low of Zydus Lifesciences Ltd stock?
A: Zydus Lifesciences Ltd stock has a 52-week high of ₹1,059.00 and a 52-week low of ₹797.05.
News Author
Aliceblue News Desk
